vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and RAMBUS INC (RMBS). Click either name above to swap in a different company.
RAMBUS INC is the larger business by last-quarter revenue ($180.2M vs $156.4M, roughly 1.2× BIOCRYST PHARMACEUTICALS INC). On growth, RAMBUS INC posted the faster year-over-year revenue change (8.1% vs 7.5%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs 16.8%).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Rambus Inc. is an American technology company that designs, develops and licenses chip interface technologies and architectures that are used in digital electronics products. The company, founded in 1990, is well known for inventing RDRAM and for its intellectual property-based litigation following the introduction of DDR-SDRAM memory.
BCRX vs RMBS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $180.2M |
| Net Profit | — | $59.9M |
| Gross Margin | — | 79.7% |
| Operating Margin | 13.6% | 34.3% |
| Net Margin | — | 33.2% |
| Revenue YoY | 7.5% | 8.1% |
| Net Profit YoY | — | -7.3% |
| EPS (diluted) | $0.00 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $156.4M | $180.2M | ||
| Q4 25 | $406.6M | $190.2M | ||
| Q3 25 | $159.4M | $178.5M | ||
| Q2 25 | $163.4M | $172.2M | ||
| Q1 25 | $145.5M | $166.7M | ||
| Q4 24 | $131.5M | $161.1M | ||
| Q3 24 | $117.1M | $145.5M | ||
| Q2 24 | $109.3M | $132.1M |
| Q1 26 | — | $59.9M | ||
| Q4 25 | $245.8M | $63.8M | ||
| Q3 25 | $12.9M | $48.4M | ||
| Q2 25 | $5.1M | $57.9M | ||
| Q1 25 | $32.0K | $60.3M | ||
| Q4 24 | $-26.8M | $62.2M | ||
| Q3 24 | $-14.0M | $48.7M | ||
| Q2 24 | $-12.7M | $36.1M |
| Q1 26 | — | 79.7% | ||
| Q4 25 | 97.7% | 78.9% | ||
| Q3 25 | 98.6% | 79.5% | ||
| Q2 25 | 98.3% | 79.8% | ||
| Q1 25 | 96.9% | 80.3% | ||
| Q4 24 | 95.4% | 80.4% | ||
| Q3 24 | 97.3% | 80.7% | ||
| Q2 24 | 98.4% | 79.7% |
| Q1 26 | 13.6% | 34.3% | ||
| Q4 25 | 64.0% | 37.2% | ||
| Q3 25 | 18.6% | 35.4% | ||
| Q2 25 | 18.2% | 36.6% | ||
| Q1 25 | 14.6% | 37.9% | ||
| Q4 24 | -3.4% | 35.9% | ||
| Q3 24 | 6.6% | 37.6% | ||
| Q2 24 | 8.0% | 30.5% |
| Q1 26 | — | 33.2% | ||
| Q4 25 | 60.5% | 33.6% | ||
| Q3 25 | 8.1% | 27.1% | ||
| Q2 25 | 3.1% | 33.6% | ||
| Q1 25 | 0.0% | 36.2% | ||
| Q4 24 | -20.4% | 38.6% | ||
| Q3 24 | -12.0% | 33.4% | ||
| Q2 24 | -11.6% | 27.3% |
| Q1 26 | $0.00 | $0.55 | ||
| Q4 25 | $1.13 | $0.58 | ||
| Q3 25 | $0.06 | $0.44 | ||
| Q2 25 | $0.02 | $0.53 | ||
| Q1 25 | $0.00 | $0.56 | ||
| Q4 24 | $-0.13 | $0.57 | ||
| Q3 24 | $-0.07 | $0.45 | ||
| Q2 24 | $-0.06 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $134.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $465.1M | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $259.0M | $134.3M | ||
| Q4 25 | $274.7M | $182.8M | ||
| Q3 25 | $212.9M | $79.2M | ||
| Q2 25 | $260.0M | $87.8M | ||
| Q1 25 | $295.1M | $132.2M | ||
| Q4 24 | $320.9M | $99.8M | ||
| Q3 24 | $96.8M | $114.0M | ||
| Q2 24 | $78.4M | $124.6M |
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $1.4B | ||
| Q3 25 | $-387.9M | $1.3B | ||
| Q2 25 | $-421.6M | $1.2B | ||
| Q1 25 | $-451.9M | $1.2B | ||
| Q4 24 | $-475.9M | $1.1B | ||
| Q3 24 | $-468.6M | $1.0B | ||
| Q2 24 | $-475.6M | $1.0B |
| Q1 26 | $465.1M | $1.5B | ||
| Q4 25 | $514.2M | $1.5B | ||
| Q3 25 | $446.4M | $1.4B | ||
| Q2 25 | $457.2M | $1.5B | ||
| Q1 25 | $480.0M | $1.4B | ||
| Q4 24 | $490.4M | $1.3B | ||
| Q3 24 | $491.3M | $1.3B | ||
| Q2 24 | $472.4M | $1.3B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
RMBS
| Product revenue | $88.0M | 49% |
| Royalties | $69.6M | 39% |
| Contract and other revenue | $22.6M | 13% |
